Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis

Mitchell, K.M., Dotson, A.L., Cool, K.M., Chakrabarty, A., Benedict, S.H., LeVine, S.M. · 2007 · Multiple Sclerosis Journal

Abstract

The iron chelator, Desferal, suppressed disease activity of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), and it has been tested in pilot trials for MS. The administration regimen of Desferal is cumbersome and prone to complications. Orally-deliverable, iron chelators have been developed that circumvent these difficulties, and the objective of this study was to test an oral chelator in EAE. SJL mice with active EAE were randomly assigned to receive deferiprone (150 mg/kg) or vehicle (water) 2×/day via gavage. EAE mice given deferiprone had significantly less disease activity and lower levels of inflammatory cell infiltrates (revealed by H&E staining) than EAE mice administered vehicle. T-cell infiltration, assessed by anti-CD3 immunohistochemical staining, also was reduced, although not significantly. Splenocytes cultured from naïve SJL mice were stimulated with anti-CD3 and anti-CD28 with or without 250 μM deferiprone. While ~39% of costimulated splenocytes without deferiprone underwent division, only ~2.8% of costimulated splenocytes with deferiprone divided and the latter cells were only 53% as viable as the former. Deferiprone had no effect on proliferation or viability of cells that were not costimulated. In summary, deferiprone effectively suppressed active EAE disease and it inhibited T-cell function. Multiple Sclerosis 2007; 13: 1118—1126. http://msj.sagepub.com

Overview

Integrity signals

Registry

Crossref · 10.1177/1352458507078916

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 71 · Cited by 51

Research works printed but not linked: 9

  1. Wu GS, 1993, Invest Ophthalmol Vis Sci, 34, 3084
  2. Sayre LM, 2005, Ann Ist Super Sanita, 41, 143
  3. Fisher AE, 2005, Drug Del, 2
  4. Norstrand IF, 1989, Clin Trials J, 26, 365
  5. Lynch SG, 2000, Cell Mol Biol (Noisy-le-grand), 46, 865
  6. Carlson NG, 2006, Drugs, 20, 433
  7. Craelius W., 1982, Arch Pathol Lab Med, 106, 397
  8. Russo C., 1997, AJNR Am J Neuroradiol, 18, 124
  9. Sobel RA, 1989, Am J Pathol, 135, 161

Metadata

Authors
Mitchell, K. M., Dotson, A. L., Cool, K. M., Chakrabarty, A., Benedict, S. H., & LeVine, S. M.
Affiliations
  • University of Kansas Medical Center (US)
  • University of Kansas (US)
Corresponding author
LeVine, S.M.
Venue
Multiple Sclerosis Journal
Published
2007-11
Volume
13
Issue
9
Pages
1118-1126
ISSN
  • 1352-4585 (ISSN-L)
  • 1477-0970
OpenAlex
W2122370406
Cited by
51
References
71
Citations by year
2026: 3 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2020: 2 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 3 · 2015: 2 · 2014: 8 · 2013: 2 · 2012: 2
FWCI
3.07
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Multiple Sclerosis Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Multiple Sclerosis Society
  • National Institute on Aging (R03AG023946, AG23946)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD-02528)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
Keywords
deferiprone, iron chelators, experimental autoimmune encephalomyelitis, multiple sclerosis, oral drug delivery, T cell proliferation, T cell function, inflammatory cell infiltration, disease activity, deferoxamine
MeSH terms
Deferiprone, Administration, Oral, Animals, Cell Division, Encephalomyelitis, Autoimmune, Experimental, Female, Iron Chelating Agents, Mice, Inbred Strains, Pyridones, Severity of Illness Index, Spleen, T-Lymphocytes, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis. https://app.cochat.ai/papers/10.1177/1352458507078916
The paper
Mitchell, K. M., Dotson, A. L., Cool, K. M., Chakrabarty, A., Benedict, S. H., & LeVine, S. M. (2007). Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458507078916

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.